Skip to content

Investigation of Urinary Biomarkers for the Detection of Prostate Cancer

Investigation of Urinary Biomarkers for the Detection of Prostate Cancer

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05454371
Acronym
URODETECT-WP2
Enrollment
0
Registered
2022-07-12
Start date
2023-12-31
Completion date
2023-12-31
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liquid Biopsy, Prostate Cancer, Urine

Keywords

First-void urine, Liquid biopsy, Oncology, Biomarker, Colli-Pee

Brief summary

The aim of this study is to investigate and possibly validate urinary biomarkers for prostate cancer. During this study the focus will be on aberrations of selected genes as prognostic or predictive value has been shown for these genes in tissue, CTC or blood derived cfDNA. Proteins will be explored in urine as well. This is a prospective study in which urine samples will be collected from healthy volunteers and urine samples and a blood sample from cancer patients with prostate cancer. The participants will be asked to provide a urine sample collected with the ColliPee® device and fill out an online questionnaire to collect usability data. Thereafter, the urine sample will be aliquoted to be used in the study to investigate the different urinary analytes.

Interventions

Colli-Pee UAS device variants will be evaluated during this study

Sponsors

Universiteit Antwerpen
CollaboratorOTHER
Novosanis NV
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Being at least 18 years old * Being able to understand and read Dutch * For cancer patients: being diagnosed with prostate cancer * For healthy volunteers: being male

Exclusion criteria

* For cancer patients: suffering from a blood cancer * For healthy volunteers: diagnosed with cancer

Design outcomes

Primary

MeasureTime frameDescription
Detection (absence/presence) of specific urinary biomarker targets (AR-V7, TMPRSS2-ERG) for prostate cancer patients measured using ddPCR.Through study completion, an average of 1 year.Comparison of target detection measured using ddPCR assays \[positive, negative or copies/µL\] in first-void urine samples from prostate cancer patients compared to age- and sex-matched healthy volunteers. (Proof of concept study)

Secondary

MeasureTime frameDescription
Detection (absence/presence) of specific biomarker targets (AR-V7, TMPRSS2-ERG) for prostate cancer patients measured using ddPCR.Through study completion, an average of 1 yearComparison of target detection measured using ddPCR assays \[positive, negative or copies/µL\] in first-void urine samples from all study participants compared to blood testing using ddPCR. (Proof of concept study)
Usability characteristics of the Colli-Pee UAS devices.Through study completion, an average of 1 yearAll study participants will receive a questionnaire regarding the usability characteristic of the Colli-Pee UAS devices. These questions cover physical information, previous experiences, and usability questions. When scores need to be given participants can score between 0 and 100%, in which 0% is a negative score and 100% is a positive score. When an opinion is asked participants can choose between very difficult, difficult, neutral, easy, and very easy. Analysis will be done using descriptive statistics.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026